387 related articles for article (PubMed ID: 16095481)
21. Amisulpride and neuroleptic malignant syndrome.
Tu MC; Hsiao CC
Chang Gung Med J; 2011; 34(5):536-40. PubMed ID: 22035899
[TBL] [Abstract][Full Text] [Related]
22. Olanzapine induced neuroleptic malignant syndrome.
Patra BN; Khandelwal SK; Sood M
Indian J Pharmacol; 2013; 45(1):98-9. PubMed ID: 23543750
[TBL] [Abstract][Full Text] [Related]
23. Examining the Features of Neuroleptic Malignant Syndrome in Anti-NMDA Receptor Encephalitis: A Case-Control Study.
Ramirez-Bermudez J; Restrepo-Martinez M; Espinola-Nadurille M; Martinez-Angeles V; Lopez-Hernandez JC; Hernandez-Vanegas LE; Martinez-Carrillo F; Ruiz-Garcia R; Rivas-Alonso V; Flores-Rivera J; Pollak TA
J Acad Consult Liaison Psychiatry; 2024; 65(3):222-230. PubMed ID: 38151160
[TBL] [Abstract][Full Text] [Related]
24. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.
Srivastava A; Borkar HA; Chandak S
Psychiatry Clin Neurosci; 2009 Feb; 63(1):119-21. PubMed ID: 19067992
[TBL] [Abstract][Full Text] [Related]
25. Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.
Supe S; Matijević V; Kondić L; Alvir D
Psychiatr Danub; 2006 Jun; 18(1-2):97-101. PubMed ID: 16804507
[TBL] [Abstract][Full Text] [Related]
26. Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome.
Tofler IT; Ahmed B
J Clin Psychopharmacol; 2003 Dec; 23(6):672-4. PubMed ID: 14624203
[No Abstract] [Full Text] [Related]
27. Neuroleptic malignant syndrome and atypical antipsychotic drugs.
Ananth J; Parameswaran S; Gunatilake S; Burgoyne K; Sidhom T
J Clin Psychiatry; 2004 Apr; 65(4):464-70. PubMed ID: 15119907
[TBL] [Abstract][Full Text] [Related]
28. [Neuroleptic malignant syndrome in a patient treated with olanzapine].
Horni G; Meirik K; Lund MB
Tidsskr Nor Laegeforen; 2003 Oct; 123(20):2867-9. PubMed ID: 14600711
[TBL] [Abstract][Full Text] [Related]
29. Antipsychotics leading to neuroleptic malignant syndrome in pregnancy.
Ghaffari N; Dossett E; Lee RH; Aghajanian P
Obstet Gynecol; 2012 Feb; 119(2 Pt 2):436-438. PubMed ID: 22270430
[TBL] [Abstract][Full Text] [Related]
30. Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.
Ahuja N; Palanichamy N; Mackin P; Lloyd A
J Psychopharmacol; 2010 Jan; 24(1):125-30. PubMed ID: 18801826
[TBL] [Abstract][Full Text] [Related]
31. Neuroleptic malignant syndrome during a change from haloperidol to risperidone.
Reeves RR; Mack JE; Torres RA
Ann Pharmacother; 2001 Jun; 35(6):698-701. PubMed ID: 11408988
[TBL] [Abstract][Full Text] [Related]
32. Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome.
Lee JW
Ann Clin Psychiatry; 2007; 19(1):9-16. PubMed ID: 17453656
[TBL] [Abstract][Full Text] [Related]
33. Neuroleptic malignant syndrome versus serotonin syndrome: the search for a diagnostic tool.
Sokoro AA; Zivot J; Ariano RE
Ann Pharmacother; 2011 Sep; 45(9):e50. PubMed ID: 21878660
[TBL] [Abstract][Full Text] [Related]
34. Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.
Berry N; Pradhan S; Sagar R; Gupta SK
Pharmacotherapy; 2003 Feb; 23(2):255-9. PubMed ID: 12587815
[TBL] [Abstract][Full Text] [Related]
35. A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole.
Rodriguez OP; Dowell MS
J Okla State Med Assoc; 2006; 99(7):435-8. PubMed ID: 17017330
[TBL] [Abstract][Full Text] [Related]
36. Neuroleptic malignant syndrome associated with olanzapine.
Johnson V; Bruxner G
Aust N Z J Psychiatry; 1998 Dec; 32(6):884-6. PubMed ID: 10084355
[TBL] [Abstract][Full Text] [Related]
37. Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.
Szota A; Ogłodek E; Araszkiewicz A
Pharmacol Rep; 2013; 65(2):279-87. PubMed ID: 23744413
[TBL] [Abstract][Full Text] [Related]
38. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations.
Picard LS; Lindsay S; Strawn JR; Kaneria RM; Patel NC; Keck PE
Pharmacotherapy; 2008 Apr; 28(4):530-5. PubMed ID: 18363536
[TBL] [Abstract][Full Text] [Related]
39. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome.
Lee JW
J Clin Psychopharmacol; 2010 Feb; 30(1):3-10. PubMed ID: 20075641
[TBL] [Abstract][Full Text] [Related]
40. Neuroleptic malignant syndrome and its controversies.
Margetić B; Aukst-Margetić B
Pharmacoepidemiol Drug Saf; 2010 May; 19(5):429-35. PubMed ID: 20306454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
